Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XRF-1021
- Development stage
- Phase 1
- Lead developer
- Shenzhen Famayi Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
XRF-1021 is an orally active, small-molecule homeodomain-interacting protein kinase 2 (HIPK2) inhibitor and dual URAT1/GLUT9 inhibitor developed by Shenzhen Famayi Pharmaceutical Technology for the treatment of gout with hyperuricemia. It lowers serum uric acid levels by inhibiting the renal uric acid transporters URAT1 and GLUT9 (both GLUT9a and GLUT9b), thereby reducing renal uric acid reabsorption and enhancing excretion. Additionally, through its inhibition of HIPK2, XRF-1021 exhibits anti-inflammatory and anti-fibrotic properties, which may alleviate renal tubular injury and tubulointerstitial fibrosis associated with chronic kidney disease and hyperuricemia.
- Other names
- XRF1021XRF-1021XRF 1021
02
Targets
ABCG2 (Breast cancer resistance protein)HIPK2 (Homeodomain-interacting protein kinase 2)GLUT9 (Glucose transporter type 9)URAT1 (Uric Acid Transporter 1)
Beyond the preview
Go deeper on XRF-1021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XRF-1021.